TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

The emergence of drug resistance is a major obstacle in the treatment of cancer patients. Here, the authors show that TRIB2 expression increases resistance to PI3K inhibition by promoting AKT activation and the subsequent FOXO inactivation and disruption of p53 function.

Bibliographic Details
Main Authors: Richard Hill, Patricia A. Madureira, Bibiana Ferreira, Inês Baptista, Susana Machado, Laura Colaço, Marta dos Santos, Ningshu Liu, Ana Dopazo, Selma Ugurel, Angyal Adrienn, Endre Kiss-Toth, Murat Isbilen, Ali O. Gure, Wolfgang Link
Format: Article
Language:English
Published: Nature Publishing Group 2017-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms14687

Internet

https://doi.org/10.1038/ncomms14687

Similar Items